Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma

Anticancer Research

Volumn 20, Issue 1 B, 2000, Pages 505-510

  Oyama, Tsunehiro ^a   Osaki, Toshihiro ^a   Nose, Naohiro ^a   Ichiki, Yoshinobu ^a   Inoue, Masaaki ^a   Imoto, Hideyuki ^a   Yoshimatsu, Takashi ^a   Kodate, Mantaro ^a   Uramoto, Hidetaka ^a   Mizoue, Tetsuya ^a   Yano, Koichi ^a   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

AgNOR; Non small cell lung cancer; p53 immunoreactivity; PCNA

Indexed keywords

CYCLINE; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CHROMOSOME NOR; CLINICAL FEATURE; FEMALE; GENDER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STAIN; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE TABLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM STAGING; NUCLEOLUS ORGANIZER REGION; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SILVER STAINING; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034078113     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Carbone DP: The biology of lung cancer. Semin Oncol 24: 388-401, 1997.
2. Greenblatt MS, Bennett WP, Hollstein M et al: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
3. Hollstein M, Sidransky D, Vogelstein B et al:p53 mutations in human cancers. Science 253: 49-53, 1991.
4. Mitsudomi T, Oyama T, Nishida K et al: p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. Annu Oncol 6(Supple. 3): s9-s13, 1995.
5. Egan M and Crocker J: Evaluation of nucleolar organizer regions in pulmonary pathology. Thorax 45: 225-232, 1990.
6. Goodpasture C and Bloom SE: Visualization of nucleolar organizer regions in mammalian chromosomes using silver staining. Chromosoma (Berl.) 53: 37-50, 1975.
7. Howell WM, Denton TE and Diamond JR: Differential staining of the satellite regions of acrocentric chromosomes. Experientia (Basal) 31: 260-262, 1975.
8. Egan MJ and Crocker J: Nucleolar organizer regions in pathology. Br J Cancer 65: 1-7, 1992.
9. Öfner D, Totsch M, Sandbichler P et al: Silver stained nucleolar organizer region proteins (Ag-NORs) as a predictor of prognosis in colon cancer. J Pathol 162: 43-49, 1990.
10. Rüschoff J, Bittinger A, Neumannn K et al: Prognostic significance of nucleolar organizing regions (NORs) in carcinomas of the sigmoid colon and rectum. Pathol Res Pract 186: 85-41, 1990.
11. Morita M, Kuwano H, Matsuda H et al: Prognostic significance of argyrophilic organizer regions in esophageal carcinoma. Cancer Res 51: 5319-5341, 1991.
12. Kaneko S, Ishida T, Sugio K et al: Nucleoler organizer regions as a prognostic indicator for stage I non-small cell lung cancer. Cancer Res 51: 4008-4011, 1991.
13. Oyama T, Mitudomi T, Yoshida Y et al: Nucleolar organizer region are indipendently associated with a shortened survival of patients with non-small cell lung cancer. Surg Oncol 2: 341-347, 1993.
14. Tan EM: Autoantibodies to nuclear antigens (ANA). Their immunobiology and medicine. Adv Immunol. 33: 167-240, 1982.
15. Miyachi K, Fritzler MJ and Tan EM: Autoantihodies to a nuclear antigen in proliferating cells. J Immunol 121: 2228-2234, 1978.
16. Prelich G, Tan C-K, Kostura M et al: Functional identity of proliferating cell nuclear antigen and a DNA polymerase-d auxiliary protain. Nature 326: 517-520, 1987.
17. Brove R, Frank R, Blundell PA et al: Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ. Nature 326: 515-517, 1987.
18. Kunkel TA, Sabatino RD and Bambara RA: Exonucleolytic proofreading by self thymus DNA polymerase-d. Proc Nath Acad Sci USA 84: 4865-4869, 1987.
19. Galand P and Degraef C: Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for marking S phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet 22: 383-392, 1989.
20. Hall PA, Levison DA, Woods AL et al: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162: 285-294, 1990.
21. Garcia RI, Coltrera MD and Grown AM: Analysis proliferative grade using PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Am J Pathol 134: 733-739, 1989.
22. Carey FA, Fabbroni G and Lamb D: Expression of proliferating cell nuclear antigen in lung cancer: a systematic study and correlation with DNA ploidy. Histopathology 20: 499-503, 1992.
23. Fontanini G, Macchiarini P, Pepe S et al: The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer. Cancer 70(6): 1520-1527, 1992.
24. Quinn, CM and Wright, NA: The clinical assesment of proliferation and growth in human tumors: evaluation of methods and applications as prognostic variables. J Pathol 160: 93-102, 1990.
25. Theunissen PHMH, Leers MPG and Bollen ECM: Proliferating cell nuclear antigen (PCNA) expression in formalin-fixed tissue of non-small cell lung carcinoma. Histopathology 20: 251-255, 1992.
26. Oyama T, Mitudomi T, Mizoue T, Ohgami A, Osaki R, Nakanishi R, Yasumoto K.: Proliferating cell nuclear antigen may be superior to argyrophilic nucleolar organizer regions in predicting shortened survival of patients with non-small cell lung cancer. Surg Oncol 4: 83-89, 1995.
27. Fontanini G, Pingitore R, Bigini D et al: Growth fraction in non-small cell lung cancer estimated by proliferating cell nuclear antigen and comparison with Ki-67 labeling and DNA flow cytometry data. Am J Pathol 141(6): 1285-1289, 1992.
28. Minna JD, Pass H, Glatstein E et al: Cancer of the lung. In: Cancer: Principles and Practice of Oncology (DeVita VT, Hellman S and Rosenberg SA. eds): Philadelphia, Lippincott. 1989, pp 591-705.
29. Murakami I, Fujiwara Y, Yamaoka N et al: Detection of p53 gene mutations in cytopatholgy and biopsy specimens from patients with lung cancer. Am J Respir Crit Care Med 154: 1117-1123, 1996.
30. Chern JH, Lee YC, Yang MH et al: Usefulness of argyrophilic nucleolar organizer regions score to differentiate suspicious malignancy in pulmonary cytology. Chest 111: 1591-1596, 1997.
31. Ascoli V, Barsotti P, Facciolo F et al: Nucleolar organiger regions in the fine needle aspiratiotes of lung tumours. Cytopathology 1: 277-286, 1990.
32. Wang KP: Transbronchial needle aspiration and percutaneous needle aspiration for staging and diagnosis of lung cancer. Clin Chest Med 16: 535-552, 1995.
33. Gasparini S, Ferretti M, Secchi EB et al: Integration of transbronchial and percutaneous approach in the diagnosis of peripheral pulmonary nodules or masses. Experience with 1,027 consecutive cases. Chest 108: 131-137, 1995.
34. Lee YC, Chang DB, Lee JM et al. Nucleolar organizer regions as a prognostic factor in surgically treated lung cancer patients. Thorac Cardiovasc Surg 44: 204-207, 1996.
35. Tormanen U, Eerola AK, Rainio P et al: Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 55: 5595-5602, 1995.
36. Ebina M, Steinberg SM, Mulshine JL et al: Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 54: 2496-2503, 1994.
37. Mountain CF, Dresler CM: Regional lymph node classification for lung cancer staging. Chest 111: 1718-1723, 1997.
38. World Health Organization: Histological typing of lung tumors (WHO), Ed. 2. Am J Clin Pathol 77: 123-136, 1982.
39. Oyama T, Osaki R, Mitudomi T, Mizoue T, Ohgami A, Nakanishi R, Sugio K, Yasumoto K: Proliferating cell nuclear antigen and argyrophilic nucleolar organizer regions in patients with thymic disease. Oncology Reports 4: 1201-1205, 1997.
40. Crocker J, Boldy JAR and Egan MJ: How should we count AgNORs? Proposals for a standardized approach. J Pathol 158: 185-188, 1989.
41. Kaplan E and Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
42. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemo Rep 50: 163-170, 1966.
43. Cox DR: Regression models and life tables. J Royal Stat Soc, Series B, 34: 187-220, 1972.
44. Esposito V, Baldi A, De Luca A et al: Prognostic value of p53 in non-small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum Pathol 28: 233-237, 1997.
45. Wiethege T, Voss B and Muller KM: p53 accumulation and proliferating-cell nuclear antigen expression in human lung cancer. J Cancer Res Clin Oncol 121: 371-377, 1995.
46. Korkolopoulou P, Oates J, Crocker J et al: p53 expression in oat and non-oat small cell lung carcinomas: correlations with proliferating cell nuclear antigen. J Clin Pathol 46: 1093-1096, 1993.
47. Fontanini G, Bigini D, Vignati S et al: p53 expression in non small cell lung cancer: clinical and biological correlations. Anticancer Res 13: 737-742, 1993.
48. Walker C, Robertson LJ, Myskow MW et al: p53 expression in normal and dysplaatic bronchial epithelium and in lung carcinomas. Br J Cancer 70: 297-303, 1994.
49. Fontanini G, Vignati S, Bigini D et al: Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic prognosis. J Pathol 174: 23-31, 1994.
50. Fontanini G, Vignati S, Bigini D et al: Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small cell lung cancer. Br J Cancer 71: 1003-1007, 1995.